1-18 of 18
Min Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie
Journal: Blood
Blood (2024) 144 (Supplement 1): 866.
https://doi.org/10.1182/blood-2024-199155
Published: 2024
Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell
Journal: Blood
Blood (2023) 142 (Supplement 1): 4461.
https://doi.org/10.1182/blood-2023-181602
Published: 2023
Journal Articles

Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies

Min Zhu, Daniela Conrado, Kamal Srinivasan, Jurriaan Brouwer-Visser, Hong Yan, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Lutz Harnisch, John D Davis
Journal: Blood
Blood (2023) 142 (Supplement 1): 1436.
https://doi.org/10.1182/blood-2023-180675
Published: 2023
Journal Articles

Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Cecilia Carpio, Manjusha Namuduri, Nazia Iqbal, Dishan Liu, Nickolas Sophos, Min Zhu, Ayesha Sabir, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Alejandro Martín García-Sancho
Journal: Blood
Blood (2023) 142 (Supplement 1): 3100.
https://doi.org/10.1182/blood-2023-179964
Published: 2023
Journal Articles

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Masood Khaksar Toroghi, Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11930–11931.
https://doi.org/10.1182/blood-2022-158412
Published: 2022
Journal Articles

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Vladimir Jankovic, Fang Wang, Hong Yan, Jingxian Cai, Carolina Leite De Oliveira, Melanie Ufkin, John D. Davis, Aafia Chaudhry, Masood Khaksar Toroghi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11560–11561.
https://doi.org/10.1182/blood-2022-158415
Published: 2022
Journal Articles

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Masood Khaksar Toroghi, Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, Hong Yan, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11912–11913.
https://doi.org/10.1182/blood-2022-158413
Published: 2022
Journal Articles

Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma

Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Masood Khaksar Toroghi, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 11579–11580.
https://doi.org/10.1182/blood-2022-158409
Published: 2022
Journal Articles

Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach

Min Zhu, Michael Dodds, Srikanth R. Ambati, Hesham Mohamed, Jason Chittenden, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 8855–8856.
https://doi.org/10.1182/blood-2022-158416
Published: 2022
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Won-Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Michelle Limei Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutierrez, Jingjin Li, Melanie Ufkin, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Jan Walewski
Journal: Blood
Blood (2022) 140 (Supplement 1): 1070–1071.
https://doi.org/10.1182/blood-2022-158406
Published: 2022
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Tae Min Kim, Michal Taszner, Seok-Goo Cho, Silvana Novelli, Steven Le Gouill, Michelle Limei Poon, Jose C. Villasboas, Rebecca Champion, Emmanuel Bachy, Stéphanie Guidez, Aránzazu Alonso Alonso, Deepa Jagadeesh, Michele Merli, David Tucker, Jingxian Cai, Carolina Leite De Oliveira, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Stefano Luminari
Journal: Blood
Blood (2022) 140 (Supplement 1): 2280–2282.
https://doi.org/10.1182/blood-2022-158404
Published: 2022
Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Arancha Alonso, MD, Miles Prince, MD, Michal Taszner, MD, Seok-Goo Cho, MD, PhD, Don A. Stevens, MD, Michelle Poon, MD, Francesca Lim, MBBS, BSc, MRCP (UK), Steven Le Gouill, MD PhD, Cecilia Carpio, MD, Mary-Margaret Keating, MD FRCPC, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ayesha Sabir, BSc, Jingjin Li, PhD, Vladimir Jankovic, MD, Min Zhu, PhD, Jurriaan Brouwer-Visser, PhD, Siyang Leng, MD MS, L. Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Kim Won Seog, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136344
Published: 2020
Journal Articles

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji, MDPhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Susan M. O'Brien, MD, Johannes Duell, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Jingjin Li, PhD, Dina M. Flink, PhD, Min Zhu, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Max S. Topp, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136659
Published: 2020
Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3176.
https://doi.org/10.1182/blood-2019-126818
Published: 2019
Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, MD PhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jeffrey A. Barnes, MD PhD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio Chavez, Johannes Duell, MD, Kevin A. David, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Robert Charnas, PhD, Srikanth R. Ambati, MBBS, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Min Zhu, PhD, Jingjin Li, PhD, Peter Gasparini, MS, Anfal Ibrahim, BS, Vladimir Jankovic, MD, Nathalie Fiaschi, PhD, Olulanu Aina, PhD, Wen Zhang, PhD, Raquel P. Deering, PhD, Sara Hamon, PhD, Gavin Thurston, PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 762.
https://doi.org/10.1182/blood-2019-122451
Published: 2019
Journal Articles

Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment

Arend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, Rupert Handgretinger, Tanya M. Trippett, Carmelo Rizzari, Christian M. Zwaan, Deepa Bhojwani, Steven G. Dubois, MD, Peter Bader, Arndt Borkhardt, Maureen O'Brien, Susan R. Rheingold, MD, Todd Michael Cooper, Kuolung Hu, Noemi Mergen, Anja Fischer, Min Zhu, Youssef Hijazi, James Whitlock, Lia Gore
Journal: Blood
Blood (2014) 124 (21): 2292.
https://doi.org/10.1182/blood.V124.21.2292.2292
Published: 2014
Journal Articles

A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Arend von Stackelberg, Gerhard Zugmaier, Rupert Handgretinger, Franco Locatelli, Carmelo Rizzari, Tanya M. Trippett, Arndt Borkhardt, MD, Susan R. Rheingold, Peter Bader, Deepa Bhojwani, MD, Todd Michael Cooper, Steven G. DuBois, Maureen M. O'Brien, MD, Christian M. Zwaan, Chris Holland, Noemi Mergen, Anja Fischer, Min Zhu, Youssef Hijazi, James Whitlock, Lia Gore, MD
Journal: Blood
Blood (2013) 122 (21): 70.
https://doi.org/10.1182/blood.V122.21.70.70
Published: 2013
Journal Articles

Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of α1-antitrypsin

Bin Zhang, Chunlei Zheng, Min Zhu, Jiayi Tao, Matthew P. Vasievich, Andrea Baines, Jinoh Kim, Randy Schekman, Randal J. Kaufman, David Ginsburg
Journal: Blood
Blood (2011) 118 (12): 3384–3391.
https://doi.org/10.1182/blood-2011-05-352815
Published: 2011
Includes: Supplemental data